Reuters logo
BRIEF-Cellectar’s radiotherapeutic PDCS demonstrate increased survival benefit using multiple doses
April 27, 2017 / 12:42 PM / 5 months ago

BRIEF-Cellectar’s radiotherapeutic PDCS demonstrate increased survival benefit using multiple doses

April 27 (Reuters) - Cellectar Biosciences Inc:

* Cellectar’s radiotherapeutic PDCS demonstrate an increased survival benefit using multiple doses in preclinical studies

* Cellectar Biosciences Inc - pancreatic cancer model demonstrates potential utility of clr 131 in solid tumors

* Cellectar Biosciences Inc - data from both of solid tumor animal studies indicate multiple doses of radiotherapeutic pdc resulted in increased survival benefit over single dose Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below